A practical reference on peptide mapping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-16 and is reviewed periodically as new material appears.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
| Property | Value | Notes |
|---|---|---|
| Primary target | MC4R | Highest reported functional activity |
| Peak plasma time | About 1 hour | Subcutaneous administration |
| Elimination half-life | A few hours | Active fragment may extend effect |
| Main clearance route | Proteolytic degradation | Not cytochrome-dependent |
| Typical assay | LC-MS/MS | Plasma quantification |
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
=== Acidity === The methyl groups of DMSO are only weakly acidic, with a pKa = 35. For this reason, the basicities of many weakly basic organic compounds have been examined in this solvent. Deprotonation of DMSO requires strong bases like lithium diisopropylamide and sodium hydride. Stabilization of the resultant carbanion is provided by the S(O)R group. The sodium derivative of DMSO formed in this way is referred to as dimsyl sodium. It is a base, e.g., for the deprotonation of ketones to form sodium enolates, phosphonium salts to form Wittig reagents, and formamidinium salts to form diaminocarbenes. The dimsyl anion is a potent nucleophile.
1961 Discovery by Leonard Hayflick of the limit of divisions for somatic cells, named the Hayflick limit. Hayflick found that normal human cells, extracted from fetus, are able to divide only about 50 times, after that they enter a senescence phase. 1969 Immunological theory of aging proposed by Roy Walford. 1974 Formation of the National Institute on Aging (NIA) – the aging of the population began to be perceived as a problem deserving state attention (and not as a problem of separate scientific societies). Since 1984, the NIA has begun to contribute in every way to the work of the National Archive of Computerized Data on Aging (NACDA). 1977 To explain aging, Thomas Kirkwood proposed the disposable soma theory. According to the theory, the organism has only a limited amount of resources that it has to allocate between different purposes (such as growth, reproduction, repair of damage). Aging occurs due to the limitation of resources that the body can afford to spend on repair. 1985 The discovery of telomerase, a ribonucleoprotein that is able to restore shortened telomeres. The discovery was made by Elizabeth Blackburn and Carol Greider. This research is based on the theoretical works of Alexey Olovnikov. The study of telomeres and telomerase required many more years and the work of many scientists around the world. For this work, in 2009, Elizabeth Blackburn, Carol Greider and Jack Szostak received the Nobel prize, in the same year Alexey Olovnikov was awarded the Demidov Prize.
=== Marriage === Seligman writes: "Unlike money, which has at most a small effect, marriage is robustly related to happiness... In my opinion, the jury is still out on what causes the proven fact married people are happier than unmarried people." (pp. 55–56). Married persons report higher levels of happiness and well-being than single people. Other data has shown a spouse's happiness depends on the happiness of their partner. When asked, spouses reported similar happiness levels to each other. The data also shows the spouses' happiness level fluctuates similarly to one another. If the husband is having a bad week, the wife will similarly report she had a bad week. There is little data on alternatives like polyamory, although one study stated wife order in polygyny did not have a substantial effect on life or marital satisfaction over all. This study also found younger wives were happier than older wives. On the other hand, at least one large study in Germany found no difference in happiness between married and unmarried people. Studies have shown that married couples are consistently happier and more satisfied with their life than those who are single. Some research findings have indicated that marriage is the only real significant bottom-up predictor of life satisfaction for men and women, and that those people who have a higher life satisfaction prior to marriage, tend to have a happier marriage. Self-reported satisfaction typically drops as the years of marriage roll on, particularly for couples who have children compared to those who do not.
== Awards and honours == Beynon received the Sigma Xi Research Award, Purdue University in 1973, the Marice F. Hasler Award in 1979, the Jozef Stefan Medal in 1980, the Medal of the Serbian Chemical Society in 1981, the Techmart Trophy of the British Technology Group in 1984, the Jan Marc Marci Medal, Czechoslovak Spectroscopic Society in 1984, the International Mass Spectrometry Society Thomson Medal in 1985, the American Chemical Society Field and Franklin Award for Outstanding Work in Mass Spectrometry in 1987, the British Mass Spectrometry Society Aston Medal in 1998, and the Italian Mass Spectrometry Society Gold Medal in 1990. He was the Founder chairman British Mass Spectrometry Society (1960), a founding member of the American Society for Mass Spectrometry (1967), and Founder President of the European Mass Spectrometry Society (1993). Beynon was elected to the Royal Society in 1971. He authored over 350 scientific publications. and several books on mass spectrometry. In 1987, Beynon was founding editor-in-chief of the journal Rapid Communications in Mass Spectrometry.
Sources: en.wikipedia.org
=== Time resolved laser fluorescence spectroscopy === Time-resolved laser fluorescence spectroscopy is a sensitive spectroscopic method able to investigate the formation of different complex species in sub-micro molar concentrations. Thanks to the great spectroscopic properties of some metal cations representatives of actinides and lanthanides, fluorescence analyses by laser excitation of ion energy levels can be carried out on monophasic and biphasic solutions. The fluorescence evolution resulting from the ion energy transitions is generally followed as a function of ligand concentration in monophasic titration experiments. The bathochromic shift of the fluorescence spectra are due to the ligand complexation. According to the postulated complexation model and the Slope Analysis on the experimental data, the stoichiometry of the major complexes can be determined. Moreover, the cumulative stability constants
On June 7, after winning the election, Ford said that the "very first item" on his agenda would be to cancel the federal carbon tax and provincial cap-and-trade programs in order to prevent motorists from being "gouged at the pumps". According to a June 28, 2018 article in The Economist, Ontario, with "Canada's second-highest public debt per person and a growing budget deficit", Ford's "poleaxing of cap and trade" would result in C$2.8bn worth of pollution permits owned by companies that could result in lawsuits. The article said that Ontario would lose C$2bn a year from the sale of pollution permits under its cap-and-trade program, which represents 1.3% of Ontario's revenue. In November 2018, the Ford government announced that it was eliminating three provincial watchdog groups, including the Environmental Commissioner of Ontario (ECO), to cut costs. Then Environmental Commissioner of Ontario (ECO), Dianne Saxe, had just submitted her 4-volume, 339-page 2018 Environmental Protection Report, entitled "Back to Basics, to the Legislative Assembly of Ontario. Saxe was a "vocal critic" of the Ford government's "actions on climate change"—"their vow to fight a federal carbon tax, pulling out of more than 700 renewable energy contracts and moving to end the Ontario Green Energy Act." Bill 57, also known as the Restoring Trust, Transparency and Accountability Act transferred the Environmental Commissioner Officer's duties to the Auditor General of Ontario.
Hydrogen peroxide has a relatively elusive and highly unstable isomer called oxywater, also known as water oxide. Its chemical formula is H2OO and its systematic IUPAC name is oxidooxidanium. It is isoelectronic to fluoroamine and is a ylide. It rapidly decomposes to form hydrogen peroxide, the reaction mechanism for which is likely a 1,2-hydrogen shift.
Sources: en.wikipedia.org
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.
Elimination is rapid, with a half-life of a few hours. An active fragment circulates after breakdown, so biological activity may outlast measurable parent drug. This is one reason single-timepoint measurements are limited.
Because breakdown is mainly proteolytic rather than cytochrome-dependent, classic metabolic interactions are less likely. Agents affecting blood pressure could still matter. Formal interaction studies are sparse.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.